U.S. markets open in 6 hours 49 minutes

RAPT Therapeutics, Inc. (RAPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
20.54-1.06 (-4.91%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close21.60
Open21.79
Bid0.00 x 800
Ask0.00 x 1000
Day's Range20.45 - 22.00
52 Week Range10.52 - 51.21
Volume135,862
Avg. Volume443,146
Market Cap504.366M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.45
Earnings DateNov 16, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • RAPT Therapeutics' (NASDAQ:RAPT) Shareholders Are Down 28% On Their Shares
      Simply Wall St.

      RAPT Therapeutics' (NASDAQ:RAPT) Shareholders Are Down 28% On Their Shares

      It's easy to match the overall market return by buying an index fund. While individual stocks can be big winners...

    • RAPT Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
      GlobeNewswire

      RAPT Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

      SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 3:40 pm Eastern Time. To access the live webcast and subsequent archived recording of the company presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.About RAPT Therapeutics, Inc. RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets, including hematopoietic progenitor kinase 1 (HPK1) and general control nonderepressible 2 (GCN2), that are in the discovery stage of development.Investor Contact: Sylvia Wheeler swheeler@wheelhouselsa.comMedia Contact: Aljanae Reynolds areynolds@wheelhouselsa.com

    • Benzinga

      5 Value Stocks In The Healthcare Sector

      What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued.Benzinga Insights has compiled a list of value stocks in the healthcare sector that may be worth watching: 1. RAPT Therapeutics (NASDAQ:RAPT) - P/E: 0.75 2. Satsuma Pharmaceuticals (NASDAQ:STSA) - P/E: 2.65 3. Triple-S Management (NYSE:GTS) - P/E: 9.26 4. Greenlane Holdings (NASDAQ:GNLN) - P/E: 6.15 5. Jaguar Health (NASDAQ:JAGX) - P/E: 0.21Most recently, RAPT Therapeutics reported earnings per share at -0.6, whereas in Q2 earnings per share sat at -0.51. RAPT Therapeutics does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Most recently, Satsuma Pharmaceuticals reported earnings per share at -0.69, whereas in Q2 earnings per share sat at -0.65. Satsuma Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Most recently, Triple-S Management reported earnings per share at 0.61, whereas in Q2 earnings per share sat at 1.76. Triple-S Management does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Greenlane Holdings's earnings per share for Q3 sits at -0.35, whereas in Q2, they were at -0.46. Greenlane Holdings does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Jaguar Health has reported Q3 earnings per share at -0.21, which has increased by 52.27% compared to Q2, which was -0.44. Jaguar Health does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.See more from Benzinga * Click here for options trades from Benzinga * Overview Of Value Stocks In The Real Estate Sector * Stocks That Hit 52-Week Lows On Monday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.